Healthy Patients

Antimicrobial resistance (AMR)

AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible.
AMR is considered the biggest global threat of Health and Food Safety.

AMR Insights

For Healthcare professionals who wish to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities.

AMR Insights is for:

  • Medical Microbiologists, Infectiologists and other specialists
  • General Practitioners, Pharmacists
  • Infection Prevention Experts and nurses
  • Medical Docters and Caretakers in nursing homes
  • Managers and Labtechnicians of Microbiological Laboratories.

Latest Topics

  •   11 April 2024

    Combating antimicrobial resistance: a paradigm shift from general to precision medicine

    Antimicrobial resistance (AMR) is a global health threat due to its various mechanisms, making treatment difficult. Precision medicine, focusing on individualized treatment for patients’ specific genetic makeup, offers a paradigm shift in addressing AMR challenges. Bacteriophages and antimicrobial peptides (AMPs) are potential alternatives to antibiotics, offering targeted therapy and broad-spectrum antimicrobial activity. Despite challenges like […]

    Read more...
  •   11 April 2024

    The Impact of Colonization by Multi Drug Resistant Bacteria on Graft Survival, Risk of Infection, and Mortality in Recipients of Solid Organ Transplant: Systematic Review and Meta-analysis

    The study aims to assess the impact of multidrug-resistant (MDR) bacteria on solid organ transplant recipients (SOTR)’s mortality, infection, or graft-loss. Data from 15,202 SOTR were analyzed, with liver transplant and VRE colonization being predominant. MDR colonization significantly increased post-transplant one-year mortality and mixed-infections across transplant types, but no impact on graft-loss. A higher association […]

    Read more...
  •   05 April 2024

    FDA Approves New Antibiotic for Three Different Uses

    The U.S. Food and Drug Administration has approved Zevtera for treating adults with Staphylococcus aureus bloodstream infections (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). The FDA is committed to promoting new antibiotic availability when they prove safe and effective. Zevtera’s efficacy was evaluated in a randomized, controlled, double-blind, […]

    Read more...

More news related to Healthy patients

Please call me back

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed